Download cv - Malaysian Orthopaedic Association

IVY CHUNG
Associate Professor
Department of Pharmacology, Faculty of Medicine
University of Malaya, 50603 Kuala Lumpur
Tel: 603-79673199 (office)
E-mail: [email protected]
EDUCATION
2007
Ph.D.
Molecular Pharmacology and Therapeutics
State University of New York at Buffalo, Buffalo, NY
Thesis advisor: Candace S. Johnson, Ph.D.
2002
B. Eng.
Biomolecular Engineering
Tokyo Institute of Technology, Tokyo, Japan
Thesis advisor: Toshihisa Ishikawa, Ph.D.
2000
Ass. Eng.
Materials Chemistry and Bioengineering
Oyama National College of Technology, Tochigi, Japan
ACADEMIC CAREER
2007- 2011
Postdoctoral research fellow
Children’s Hospital Boston/Harvard Medical School, Boston, MA
Advisor: Bruce R. Zetter, Ph.D.
2011- current
Associate Professor
Department of Pharmacology, Faculty of Medicine, University of Malaya, Malaysia
AWARDS
2007
Dissertation Award for Excellence in Cancer Research, Roswell Park Cancer Institute
2007
Y2K7 The Young Einstein Decade Lectureship Award, Roswell Park Cancer Institute
2006
Scholar-in-Training Award-AACR Special Conference in Cancer Research
Innovation in Prostate Cancer Research
2006
Scholar-in-Training Award-AACR Special Conference in Cancer Research
Anti-Angiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back
2002-2007
Ph.D. Graduate Fellowship, Roswell Park Cancer Institute
2000
Excellent Performance in Academy Award, Chemical Society of Japan
2000
Excellent Academic Record Award, Oyama National College of Technology
1995-2002
College Scholarship to Japan, Department of Public Service, Malaysia
Ivy Chung, Ph.D.
FUNDING INFORMATION
Present Funding:
2013-2014
Role: PI
UM-Harvard Collaboration Initiatives
RM300,000
2013-2015
Role: PI
UM Nobel Endeavour Program
Towards a Successful Career in Cancer Research (postgraduate student training grant)
RM60,000
2013-2015
Role: PI
University Malaya Research Grant, Malaysia
Role of Cancer-Associated Fibroblasts in the Progression of Endometrial Cancer
RM120,000
2012-2013
Role: Co-PI University Malaya Research Grant, Malaysia
Stromal Fibroblast as Mediators of Chemoresistance in Oral Carcinoma Cells
RM55,000
2011 –2013
Role: PI
University Malaya Research Grant, Malaysia
RM104,500
Molecular Determinants Underlying the Progression of Normal Endometrium to Endometriosis,
Endometrioid Adenocarcinoma of the Ovary and to Endometrial Cancer
2011 –2013
Role: PI
UM Cancer Institute High Impact Grant, Malaysia
Targeting Tumor-Stellate Cells Interaction for Novel Therapeutics in Pancreatic Cancer
RM600,000
Past Funding:
2010 –2011
Role: PI
Department of Defense, USA
US$100,000
PC094329 Prostate Cancer Post-doctoral Training Grant: Benzimidazole as Novel Therapy for HormoneRefractory Metastatic Prostate Cancer
2005 – 2007
Role: PI
Department of Defense, USA
US$100,000
PC050202 Prostate Cancer Pre-doctoral Training Grant: Molecular Mechanisms of Differential Effects of
Calcitriol on Endothelial Cells Isolated from Prostate Tumor and Normal Microenvironment
RESEARCH EXPERIENCE
Faculty of Medicine, University of Malaya
Associate Professor, Pharmacogenomics Laboratory
Kuala Lumpur, Malaysia
2011 – present
1) Targeting stroma-mediated pancreatic adenocarcinoma progression and chemoresistance
2) Molecular determinants underlying progression of endometriosis to endometrial cancer
3) Pharmacogenomic studies on genetic susceptibility in prostate, breast and lympho-hyperproliferative
diseases
4) Establishing primary cell cultures from human tumor specimen
Harvard Medical School, Children’s Hospital Boston
Postdoctoral Fellow; Advisor: Bruce Zetter, PhD.
1) Development of therapeutic agents targeting metastatic prostate cancer
- Designed high-throughput screening and discovery of potential lead drugs in vitro
Boston, MA, USA
2007 - 2011
Ivy Chung, Ph.D.
-
Improvised drug formulation for increased drug delivery in vivo
Determined drug therapeutic efficacy in preclinical animal models of metastatic cancer
Analyzed drug combination in vitro and in vivo for better therapeutic efficacy
Elucidated mechanism of actions underlying therapeutic drug-induced apoptosis
2) Role of miRNA in paclitaxel-resistant cancers
- Established a new model of secondary paclitaxel-resistance in tumors in vivo
- Determined the correlation and functional role of miRNA-135a in paclitaxel resistance
3) Role of tyrosinase in regulating fibromodulin-mediated tumor progression
- Established a novel metastatic in vivo model of melanoma tumor
- Determined the mechanism underlying fibromodulin-mediated tumor migration and invasion
4) Role of stromal regulation in progression of metastatic pancreatic cancer
- Developed tumor-stromal model using transgenic pancreatic adenocarcinoma mouse model
- Determined effects of pancreatic stellate cells on tumor progression
Roswell Park Cancer Institute, SUNY at Buffalo, USA
Buffalo, NY
Graduate Student; Advisor: Candace S. Johnson, PhD.
2002 – 2007
Tumor vasculature as a therapeutic target for calcitriol in cancer
- Established endothelial cell primary cultures from mouse and human normal and tumor tissues
- Utilized molecular approaches to examine vitamin D receptor signaling axis and epigenetic mechanism
in tumor and normal endothelium
- Examined the role of vitamin D receptor in tumor and non-tumor angiogenesis in vivo
Tokyo Institute of Technology, Japan
Tokyo, Japan
College Student; Advisor: Toshihisa Ishikawa, PhD.
2000 – 2002
Profiling of ATP-binding cassette (ABC) transporters gene expression in human leukemia cells
- Designed human specific ABC transporter gene expression assay using quantitative real-time PCR
Oyama National College of Technology, Japan
Tochigi, Japan
Diploma Student; Advisor: Hiroyuki Saito, PhD.
1999 – 2000
Organic synthesis of various thiol compounds
- Researched on organic synthesis and analytical chemistry of sulfur-containing compounds for the use of
biodegradable polymers
Sankyo Co. Ltd
Kao Corporation
Summer intern
Investigated various methodologies in computational chemistry and organic synthesis
TEACHING AND TRAINING RESPONSIBILITIES
University of Malaya, Kuala Lumpur
PhD candidates – Varatha Rajan (2009 – present)
Wu Yuan Seng (2011 – present)
Kavita S. Subramaniam (2011 – present)
Lai Sook Ling (2013 – present)
Kwong Soke Chee (2014- present)
Tokyo, Japan
Tochigi, Japan
1998
Ivy Chung, Ph.D.
Undergraduate student – Yap Chee Voon (Bachelor of Biomedical Sciences,UM) (2013-2014)
Wee Yong Kiat (Bachelor of Bioinformatics, Multimedia University) (2014)
Research assistants – Lai Sook Ling (2012 – 2013)
Wong Mei Szin (2013 – 2013)
Ala Abu Hammattah (2013)
Intan Sofia Omar (2013 - present)
Harvard Medical School, Children’s Hospital, Boston, MA
Supervision of graduate student – daily mentorship for 12 weeks
2009
Annie Vo Phong
Biological and Biomedical Sciences/Harvard Medical School
2009-2010
Arianne Wilson
Research Assistant II
Roswell Park Cancer Institute, SUNY at Buffalo
Supervision of high school students
2005- 2006 Risa Trump
Roswell Park Cancer Center Summer Student Program
PROFESSIONAL ASSOCIATION AND POSITIONS
2001-2007
200520062006200720112011-
Member, ATP-Binding Receptors (ABC) Society Japan
Associate member, Association for Cancer Research (AACR) (USA)
Member, AACR-Tumor Microenvironment Working Group (USA)
Member, AACR-Women in Cancer Research Working Group (USA)
Member, Association for Women in Science (AWIS) (USA)
Member, Malaysian Association for the Study of Obesity (Malaysia)
Member, Malaysian Society of Physiology and Pharmacology (Malaysia)
EDITORIAL ACTIVITIES
Journal of Health and Translational Medicine (sub-editor, 2012-2013; editor, 2013-present)
Oncology (ad hoc reviewer, 2006-present)
Cell Adhesion and Migration (ad hoc reviewer, 2010-present)
PATENT
Compositions for the Treatment of Metastatic Cancer and Methods of Use Thereof. Inventors: Bruce R.
Zetter, Ivy Chung and Courtney Barrow. U.S. CMCC 1653 61/180,029; International PCT/US10/35578.
Use of MicroRNA to Detect and Reverse Drug Resistance in Tumor Cells. Inventors: Bruce R. Zetter, Amy
Holleman and Ivy Chung. US. CMCC 2258 61/471,565
BOOK CHAPTER
Chung, I. Tumor fibroblasts: pivotal players in drug resistance. In: Morais, C. ed. Advances in drug
resistance research, Nova Science Publishers, N.Y., USA. (In Press)
Ivy Chung, Ph.D.
PUBLICATIONS
1. Banyard J, Chung I, Wilson A, Vetter G, Le Bechec A, Bielenberg D and Zetter BR. Regulation of
epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Scientific
Reports 3:3151 (2013). IF: 2.9 (Tier-1)
2. Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD and di
Magliano MP. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling
activation and oxidative stress resistance. Cancer Research 73(20):6359-74 (2013). IF: 8.65 (Tier-1)
3. Subramaniam KS, Tham ST, Zahurin M, Woo YL, Noor Azmi MA and Chung I. Cancer-associated
fibroblasts promote proliferation of endometrial cancer cells. PLoS ONE 8(7): e68923. (2013). IF: 3.9
(Tier-1)
4. Lee ML, Chung I, Fung SY, Kanthimathi MS and Tan NH. Anti-proliferative activity of king cobra
(Ophiophagus hannah) venom L-amino acid oxidase. Basic & Clinical Pharmacology & Toxicology doi:
10.1111/bcpt.12155 (2013). IF: 2.12 (Tier-3)
5. Rajavel V, Sattar MZ, Chung I, Abdulla MA, Kassim NM and Abdullah NA. Antioxidant and prooxidant effects of oil palm (Elaeis guineensis) leaves extract in experimental diabetic nephropathy: a
duration-dependent outcome. BMC Complementary and Alternative Medicine 13(1):242 (2013). IF: 2.24
(Tier-2)
6. Chung I, Godoy AS*, Montecinos V, Buttyan R, Johnson CS and Smith GA. Role of androgen and
vitamin D receptors in endothelial cells from benign and malignant human prostate. American Journal of
Physiology – Endocrinology & Metabolism 304(11):E1131-9 (2013). IF: 4.5 (Tier-1)
7. Spivey KA, Chung I, Banyard J, Adini I, Feldman HA and Zetter BR. A role of collagen XXIII in cancer
cell adhesion, anchorage-independence and metastasis. Oncogene 31 (18):2362-72 (2012). IF: 6.3 (Tier-1)
8. Olsen RR, Chung I and Zetter BR. Knockdown of antizyme inhibitor decreases prostate tumor growth in
vivo. Amino Acids 42 (2-3):549-558 (2012).
9. Chung I, Holleman A*, Olsen RR, Kwak B and Zetter BR. miR-135a as potential biomarker for
development of taxane resistance in human cancer. (*, shared first authorship). Oncogene 30 (43):43864398 (2011). IF: 6.3 (Tier-1)
10. Rummel N, Chung I and Shaikh Badar. Determination of albendazole, fenbendazole, and their
metabolites in mice plasma by high performance liquid chromatography. J. Pharmaceutical and
Biomedical Analysis 34 (18): 2211-2223 (2011). IF:2.94 (Tier-2)
11. Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, Olsen RR, Waghorne C and Zetter BR. Rescue of
paclitaxel sensitivity by repression of prohibitin 1 in drug-resistant cancer cells. Proceedings of the
National Academy of Sciences 107(6):2503-2508 (2010). IF:9.6 (Tier-1)
12. Johnson CS, Chung I and Trump DL. Review: The role of vitamin D on normal and tumor endothelium.
Journal of Steroid Biochemistry and Molecular Biology 121(1-2):338-42 (2010). IF: 3.9 (Tier-2)
Ivy Chung, Ph.D.
13. Chung I, Han GZ, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL and Johnson CS. Role of
vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and
tumor angiogenesis in vivo. Cancer Research 69(3):967-975 (2009). IF: 8.65 (Tier-1)
14. Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, Noguchi N, Kuo MT and Ishikawa T. Nrf2dependent and –independent nduction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2
cells under oxidative stress. Journal of Experimental Therapeutics and Oncology 6(4):335-348 (2007).
15. Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS and Trump DL. Epigenetic
silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by
calcitriol. Journal of Biological Chemistry 282(12):8704-14 (2007). IF:5.3 (Tier-1)
16. Chung I, Yu WD, Karpf AR, Flynn G, Bernardi RJ, Modzelewski RA, Johnson CS and Trump DL. Antiproliferative effects of calcitriol on endothelial cells derived from two different microenvironments. J.
Steroid Biochemistry and Molecular Biology 103(3-5):768-70 (2007). IF:3.9 (Tier-2)
17. Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS and Trump DL. Calcitriol (1,25dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial
cells and induces apoptosis. Oncology 70(6):447-457 (2007). IF:2.2 (Tier-3)
18. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS and Trump DL. Differential antiproliferative effects
of calcitriol on tumor-derived and Matrigel-derived endothelial cells. Cancer Research 66: 8565-8573
(2006). IF: 8.65 (Tier-1)
ORAL PRESENTATIONS
Chung I. Targeting the Fibroblasts in the Microenvironment of Endometrial Cancer. Malaysian Institute of
Medical Laboratory Sciences (MIMLS) 24th National Scientific Conference, Kuala Lumpur, Malaysia (2013).
Chung I. A novel mechanism of microRNA-induced paclitaxel resistance in tumor cells. Folkman Research
Day, Children’s Hospital Boston, Harvard Medical School, Boston, MA (2010).
Chung I. Benzimidazoles as novel therapy for castrate-resistant metastatic prostate cancer. Folkman WorkIn-Progress Seminar, Children’s Hospital Boston, Harvard Medical School, Boston, MA (2010).
Chung I. Differential anti-proliferative effects of calcitriol on endothelial cells isolated from tumor and nontumor microenvironments. Y2K7 The Young Einstein Decade Lectureship, Roswell Park Cancer Institute,
Buffalo, NY (2007).
Chung I, Muindi J, Johnson CS and Trump DL. Role of vitamin D and CYP24 in Prostate Vasculature.
Innovative Minds in Prostate Research Today (IMPaCT) Meeting (organized by Department of Defense).
Atlanta, GA (2007).
Chung I, Karpf AR, Muindi JR, Johnson CS and Trump DL. Epigenetic silencing of CYP24 in tumorderived endothelial cells (TDEC) contributes to selective growth inhibition by calcitriol. 13th Workshop on
Vitamin D at Victoria, BC, Canada (2006).